ClinicalTrials.gg
CompletedNCT04307940Updated Jul 14, 2022Results posted

Study to Collect Information on How Well the Study Drug Naproxen Sodium Tablets Works Compared to Hydrocodone/Acetaminophen Tablets in Order to Relieve Pain in Participants Experiencing Moderate to Severe Pain After Having Their Wisdom Teeth Removed

A Phase 4 interventional study of Naproxen Sodium (Aleve, BAY117031) and Hydrocodone/Acetaminophen in Pain, sponsored by Bayer. Completed at 1 site in United States. Open to participants aged 18 Years to 40 Years. Per ClinicalTrials.gov, last updated 2022-07-14.

Sponsored by Bayer · Phase 4, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
221
Allocation
Randomized
Ages
18 Years to 40 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-20

Among 25 studies testing naproxen in Pain — 1 open to participants now, 2 under way, none of them phase 3. Naproxen · Pain.

Enrollment
9th of 25
221 · median 100
Started
2020
the only one that year
Phase 4
9 of 25
none open now
Registered
19th of 25
by date
Lead sponsor
9 of 25
Bayer

Among the 25 studies testing naproxen in Pain, this one is the 9th largest by enrollment, is the only one that started in 2020, is one of 9 in phase 4, and was the 19th registered.

Pain

10,076 studies on the registry are indexed under Pain; 1,648 are open to participants now.

Browse Pain studies →

Open to participants now

1 of the 25 studies testing naproxen in Pain is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

About naproxen

Naproxen: first FDA approval 1976 (NAPROSYN). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 928 Pain studies recruiting now, 384 (41%) set no upper age limit and 432 (47%) stop at 75 or younger; 145 take children under 18; 220 take healthy volunteers.

This study: 18 Years to 40 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 25 studies testing naproxen in Pain, or all of them as a file.
02

Study summary

With this study researchers want to collect information on how long the pain relief lasts after a fixed dose of naproxen sodium or hydrocodone/acetaminophen or placebo (contains no medication) over 12 hours in subjects experiencing moderate to severe pain after having their wisdom teeth removed. Naproxen Sodium (Aleve®) is a drug that is used for the temporary relief of minor aches and pains.

Hydrocodone/Acetaminophen is a combination drug used to relieve moderate to severe pain. It contains an opioid (narcotic) pain reliever (hydrocodone) and a non-opioid pain reliever (acetaminophen).

03

Conditions studied

  • Pain

Browse trials for

Keywords

  • Postsurgical Dental Pain
04

Who can participate

Ages eligible
18 Years to 40 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Healthy, ambulatory, male or female volunteers 18 to 40 years of age;
  • Subjects will undergo surgical extraction of three or four third molars, two of which must be mandibular molars. Maxillary third molars may be removed regardless of impaction level. The mandibular extractions must have a trauma rating of mild or moderate and meet one of the following scenarios:

    • two full bony impactions
    • two partial bony impactions
    • one full bony impaction in combination with one partial bony impaction Supernumerary teeth present may also be removed at the discretion of the oral surgeon;
  • Have not consumed alcoholic beverages, or foods and beverages containing caffeine (examples; coffee, tea, chocolate, and colas) after midnight prior to surgery and agree not to consume any of these foods or beverages throughout their stay at the study site;
  • Use of only short-acting local anesthetic (e.g., mepivacaine or lidocaine) preoperatively, with or without a vasoconstrictor and nitrous oxide at the discretion of the Investigator;
  • Have moderate to severe postoperative pain on the Categorical Pain Intensity Scale (a score of at least 2 on a 4 point scale) and a score of ≥ 5 on the 0-10 pain intensity NRS within 4.5 hours postsurgery;
  • Ability to understand and follow study-related instructions;
  • Be willing and able to participate in all scheduled visits, treatment plan, and trial procedures according to the clinical protocol;

Exclusion criteria

Exclusion Criteria:

  • History of to naproxen sodium, hydrocodone/acetaminophen, ibuprofen, NSAIDS, aspirin, similar pharmacological agents, local anesthetics, rescue medication or components of the products;
  • Evidence or history of (in the judgment of the investigator) hematological, renal, endocrine, pulmonary, gastrointestinal, cardiovascular (including hypertension), hepatic, psychiatric, neurologic diseases, or within the last 5 years;
  • Subjects with the following medical conditions may be eligible at the discretion of the investigator: ADHD on a stable dose regimen of methylphenidate/(dextro)amphetamine for at least 6 months; subjects with hypothyroidism on a stable dose of synthetic thyroid hormone for at least 6 months;
  • Have received any form of treatment in the form of medication for depression in the past 6 months or any form of psychotropic agent (including selective serotonin uptake inhibitors [SSRI] but excluding ADHD medications described above) within the last 6 months;
  • Use of any OTC or prescription medications with which the administration of naproxen, hydrocodone/acetaminophen, acetaminophen, ibuprofen, any other NSAID, (e.g., tramadol) or if a medication is ;
  • Females who are planning to become pregnant, pregnant or lactating;
  • Habituation to analgesic drugs including opioids (i.e., routine use of oral analgesics 5 or more times per week for greater than 3 weeks within the past 2 years);
  • Alcoholism or drug abuse within 2 years prior to the Screening Visit or routine consumption of 3 or more alcohol containing beverages per day; Alcohol containing beverages are defined as one beer (5%), one glass of wine (11%) and one shot (40%) hard liquor;
  • Surgeon's trauma rating of severe following surgery;
  • Unwilling or unable to comply with all requirements outlined in the protocol;
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
221 participants (actual)

Study arms

  • Experimental
    Naproxen sodium

    After completion of the surgical teeth extractions, qualified participants will be randomized into one of three treatments with a 2:2:1 ratio. (Naproxen sodium=2, Hydrocodone/Acetaminophen=2, Placebo=1)

    Drug: Naproxen Sodium (Aleve, BAY117031)

  • Active comparator
    Hydrocodone/Acetaminophen

    After completion of the surgical teeth extractions, qualified participants will be randomized into one of three treatments with a 2:2:1 ratio. (Naproxen sodium=2, Hydrocodone/Acetaminophen=2, Placebo=1)

    Drug: Hydrocodone/Acetaminophen

  • Placebo comparator
    Placebo

    After completion of the surgical teeth extractions, qualified participants will be randomized into one of three treatments with a 2:2:1 ratio. (Naproxen sodium=2, Hydrocodone/Acetaminophen=2, Placebo=1)

    Drug: Placebo

Interventions

  • DrugNaproxenStudies of NaproxenNaproxen pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    220 mg per tablet, two tablets (440 mg), intake a single dose orally.

  • DrugHydrocodone/Acetaminophen

    5/325 mg per tablet, two tablets (10/650 mg), intake a single dose orally.

  • DrugPlacebo

    two tablets, intake a single dose orally.

06

What researchers measure

Primary outcomes

  1. Sum of Pain Intensity Difference Over 12 Hours (SPID 0-12)

    Pain intensity is measured using Numerical Rating Scale (from 0 to 10: 0 = no pain, 10 = worst possible pain). For each post dose time point, pain intensity difference (PID) is derived by subtracting the pain intensity at the post dose time point from the baseline intensity score (baseline score - post-baseline score). A positive difference is indicative of improvement. Sum of Pain Intensity Differences (SPIDs) was calculated by multiplying the PID score at each post-dose time point by the duration (in hours) since the preceding time point and then summing these values over the specific time period. SPID over 12 hours ranges from -120 to 120. A higher value indicates a better pain reduction.

    Time frame: Up to 12 hours postdose

Secondary outcomes

  1. Total Pain Relief Over 12 Hours (TOTPAR 0-12)

    Pain relief is measured using Categorical Pain Relief Rating Scale (0 = No relief, 1 = A little relief, 2 = Some relief, 3 = A lot of relief, 4 = Complete relief). Total Pain Relief is calculated as the area under the curve of pain relief score over time for the given time period by multiplying the pain relief score at each time point by the duration (in hours) since the preceding time point and then summing these values over the specific time period. TOTPAR over 12 hours ranges from 0 to 48, a higher value indicates more pain relief.

    Time frame: Up to 12 hours postdose

  2. Total Pain Relief Over 6 Hours (TOTPAR 0-6)

    Pain relief is measured using Categorical Pain Relief Rating Scale (0 = No relief, 1 = A little relief, 2 = Some relief, 3 = A lot of relief, 4 = Complete relief). Total Pain Relief is calculated as the area under the curve of pain relief score over time for the given time period by multiplying the pain relief score at each time point by the duration (in hours) since the preceding time point and then summing these values over the specific time period. TOTPAR over 6 hours ranges from 0 to 24, a higher value indicates more pain relief.

    Time frame: Up to 6 hours postdose

  3. Sum of Pain Intensity Difference Over 6 Hours (SPID 0-6)

    Pain intensity is measured using Numerical Rating Scale (from 0 to 10: 0 = no pain, 10 = worst possible pain). For each post dose time point, pain intensity difference (PID) is derived by subtracting the pain intensity at the post dose time point from the baseline intensity score (baseline score - post-baseline score). A positive difference is indicative of improvement. Sum of Pain Intensity Differences (SPIDs) was calculated by multiplying the PID score at each post-dose time point by the duration (in hours) since the preceding time point and then summing these values over the specific time period. SPID over 6 hours ranges from -60 to 60. A higher value indicates a better pain reduction.

    Time frame: Up to 6 hours postdose

  4. Number of Participants Required or Did Not Reqiure Rescue Pain Medication

    Time frame: Up to 12 hours postdose

  5. Amount of Rescue Medication

    To quantify the use of opioid analgesics in treatment of post-operative dental pain, the amount of rescue medications (opioids) was converted to a standard unit, which was Morphine Milligram Equivalent (MME) using below formula: MME/Day = Strength per Unit × (Number of units / Days supply) × MME conversion factor

    Time frame: Up to 12 hours postdose

  6. Time to First Use of Rescue Medication

    If a subject did not take the rescue medication during the treatment period, (s)he was censored at the time of last assessment.

    Time frame: Up to 12 hours postdose

  7. Duration of Pain at Least Half Gone Over 12 Hours

    Time frame: Up to 12 hours postdose

  8. Duration of Pain at Least Half Gone Over 6 Hours

    Time frame: Up to 6 hours postdose

07

Results

Posted Oct 7, 2021

Participant flow

Study was conducted at one center in the US between 12-MAR-2020 (first participant first visit) and 05-OCT-2020 (last participant last visit).

Participant flow — Overall Study
MilestoneNaproxen SodiumHydrocodone / APAPPlacebo
Started908744
Completed858442
Not completed532
Withdrew: Adverse event100
Withdrew: Withdrawal by subject231
Withdrew: Lost to follow-up201

Outcome measures

PrimarySum of Pain Intensity Difference Over 12 Hours (SPID 0-12)

Pain intensity is measured using Numerical Rating Scale (from 0 to 10: 0 = no pain, 10 = worst possible pain). For each post dose time point, pain intensity difference (PID) is derived by subtracting the pain intensity at the post dose time point from the baseline intensity score (baseline score - post-baseline score). A positive difference is indicative of improvement. Sum of Pain Intensity Differences (SPIDs) was calculated by multiplying the PID score at each post-dose time point by the duration (in hours) since the preceding time point and then summing these values over the specific time period. SPID over 12 hours ranges from -120 to 120. A higher value indicates a better pain reduction.

Time frame:
Up to 12 hours postdose
Reported as:
Least squares mean · Scores on a scale*hours
Sum of Pain Intensity Difference Over 12 Hours (SPID 0-12)
Scores on a scale*hoursNaproxen SodiumHydrocodone / APAPPlacebo
Sum of Pain Intensity Difference Over 12 Hours (SPID 0-12)53.20 ± 3.0938.39 ± 3.1413.57 ± 4.35
Statistical analysis
  • Naproxen Sodium vs Hydrocodone / APAP · ANCOVA · p = 0.001 (All p-values were presented using two-sided test with alpha 0.05 and were considered statistically significant.) · Ls mean difference: 14.81 · 95% CI 6.10 to 23.51
  • Naproxen Sodium vs Placebo · ANCOVA · p = <0.001 (All p-values were presented using two-sided test with alpha 0.05 and were considered statistically significant.) · Ls mean difference: 39.63 · 95% CI 29.08 to 50.18
  • Hydrocodone / APAP vs Placebo · ANCOVA · p = <0.001 (All p-values were presented using two-sided test with alpha 0.05 and were considered statistically significant.) · Ls mean difference: 24.82 · 95% CI 14.26 to 35.39
SecondaryTotal Pain Relief Over 12 Hours (TOTPAR 0-12)

Pain relief is measured using Categorical Pain Relief Rating Scale (0 = No relief, 1 = A little relief, 2 = Some relief, 3 = A lot of relief, 4 = Complete relief). Total Pain Relief is calculated as the area under the curve of pain relief score over time for the given time period by multiplying the pain relief score at each time point by the duration (in hours) since the preceding time point and then summing these values over the specific time period. TOTPAR over 12 hours ranges from 0 to 48, a higher value indicates more pain relief.

Time frame:
Up to 12 hours postdose
Reported as:
Least squares mean · Scores on a scale*hours
Total Pain Relief Over 12 Hours (TOTPAR 0-12)
Scores on a scale*hoursNaproxen SodiumHydrocodone / APAPPlacebo
Total Pain Relief Over 12 Hours (TOTPAR 0-12)28.41 ± 1.3621.31 ± 1.3910.63 ± 1.92
SecondaryTotal Pain Relief Over 6 Hours (TOTPAR 0-6)

Pain relief is measured using Categorical Pain Relief Rating Scale (0 = No relief, 1 = A little relief, 2 = Some relief, 3 = A lot of relief, 4 = Complete relief). Total Pain Relief is calculated as the area under the curve of pain relief score over time for the given time period by multiplying the pain relief score at each time point by the duration (in hours) since the preceding time point and then summing these values over the specific time period. TOTPAR over 6 hours ranges from 0 to 24, a higher value indicates more pain relief.

Time frame:
Up to 6 hours postdose
Reported as:
Least squares mean · Scores on a scale*hours
Total Pain Relief Over 6 Hours (TOTPAR 0-6)
Scores on a scale*hoursNaproxen SodiumHydrocodone / APAPPlacebo
Total Pain Relief Over 6 Hours (TOTPAR 0-6)14.53 ± 0.6112.69 ± 0.625.14 ± 0.87
SecondarySum of Pain Intensity Difference Over 6 Hours (SPID 0-6)

Pain intensity is measured using Numerical Rating Scale (from 0 to 10: 0 = no pain, 10 = worst possible pain). For each post dose time point, pain intensity difference (PID) is derived by subtracting the pain intensity at the post dose time point from the baseline intensity score (baseline score - post-baseline score). A positive difference is indicative of improvement. Sum of Pain Intensity Differences (SPIDs) was calculated by multiplying the PID score at each post-dose time point by the duration (in hours) since the preceding time point and then summing these values over the specific time period. SPID over 6 hours ranges from -60 to 60. A higher value indicates a better pain reduction.

Time frame:
Up to 6 hours postdose
Reported as:
Least squares mean · Scores on a scale*hours
Sum of Pain Intensity Difference Over 6 Hours (SPID 0-6)
Scores on a scale*hoursNaproxen SodiumHydrocodone / APAPPlacebo
Sum of Pain Intensity Difference Over 6 Hours (SPID 0-6)28.41 ± 1.4624.35 ± 1.486.23 ± 2.05
SecondaryNumber of Participants Required or Did Not Reqiure Rescue Pain Medication
Time frame:
Up to 12 hours postdose
Reported as:
Count of participants · Participants
Number of Participants Required or Did Not Reqiure Rescue Pain Medication
ParticipantsNaproxen SodiumHydrocodone / APAPPlacebo
Number of participants required rescue pain medication184329
Number of participants did not require any rescue pain medication684014
SecondaryAmount of Rescue Medication

To quantify the use of opioid analgesics in treatment of post-operative dental pain, the amount of rescue medications (opioids) was converted to a standard unit, which was Morphine Milligram Equivalent (MME) using below formula: MME/Day = Strength per Unit × (Number of units / Days supply) × MME conversion factor

Time frame:
Up to 12 hours postdose
Reported as:
Mean · Morphine Milligram Equivalent (MME)
Amount of Rescue Medication
Morphine Milligram Equivalent (MME)Naproxen SodiumHydrocodone / APAPPlacebo
Amount of Rescue Medication7.8 ± 3.089.3 ± 4.0210.5 ± 4.50
SecondaryTime to First Use of Rescue Medication

If a subject did not take the rescue medication during the treatment period, (s)he was censored at the time of last assessment.

Time frame:
Up to 12 hours postdose
Reported as:
Median · Hours
Time to First Use of Rescue Medication
HoursNaproxen SodiumHydrocodone / APAPPlacebo
Time to First Use of Rescue MedicationNA (NA to NA)10.42 (8.27 to NA)2.57 (1.83 to 7.60)
SecondaryDuration of Pain at Least Half Gone Over 12 Hours
Time frame:
Up to 12 hours postdose
Reported as:
Least squares mean · Hours
Duration of Pain at Least Half Gone Over 12 Hours
HoursNaproxen SodiumHydrocodone / APAPPlacebo
Duration of Pain at Least Half Gone Over 12 Hours8.87 ± 0.466.57 ± 0.463.31 ± 0.64
SecondaryDuration of Pain at Least Half Gone Over 6 Hours
Time frame:
Up to 6 hours postdose
Reported as:
Least squares mean · Hours
Duration of Pain at Least Half Gone Over 6 Hours
HoursNaproxen SodiumHydrocodone / APAPPlacebo
Duration of Pain at Least Half Gone Over 6 Hours4.60 ± 0.224.08 ± 0.221.49 ± 0.31

Adverse events

Collected over From first dose of the study drug administration until end of study treatment, up to 1 day. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Naproxen Sodium0/90 (0%)0/90 (0%)2/90 (2.2%)
Hydrocodone/APAP0/87 (0%)0/87 (0%)33/87 (37.9%)
Placebo0/44 (0%)0/44 (0%)11/44 (25%)
Most frequent other events
Most frequent other events
EventNaproxen SodiumHydrocodone/APAPPlacebo
Gastrointestinal disordersGastrointestinal disorders1/9030/879/44
Nervous system disordersNervous system disorders1/909/874/44
General disorders and administration site conditionsGeneral disorders0/901/870/44

Baseline characteristics

Safety Population: included all subjects who were randomized and received at least one dose of study drug

Age, Continuous
Age, Continuous(Years)Naproxen SodiumHydrocodone / APAPPlaceboTotal
Mean19.3 ± 1.6219.3 ± 1.6919.3 ± 2.0019.3 ± 1.72
Sex: Female, Male
Sex: Female, Male(Participants)Naproxen SodiumHydrocodone / APAPPlaceboTotal
Female504220112
Male404524109
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Naproxen SodiumHydrocodone / APAPPlaceboTotal
Hispanic or Latino1818642
Not Hispanic or Latino726938179
Unknown or Not Reported0000
Baseline pain intensity
Baseline pain intensity(Participants)Naproxen SodiumHydrocodone / APAPPlaceboTotal
Moderate34361787
Severe565127134
08

Study locations

1 site
  • JBR Clinical Research
    Salt Lake City, Utah 84107, United States
09

References and documents

Publications

  • Cooper SA, Desjardins PJ, Bertoch T, Paredes-Diaz A, Troullos E, Tajaddini A, Centofanti R, An R, Morella D. Analgesic efficacy of naproxen sodium versus hydrocodone/acetaminophen in acute postsurgical dental pain: a randomized, double-blind, placebo-controlled trial. Postgrad Med. 2022 Jun;134(5):463-470. doi: 10.1080/00325481.2021.2008180. Epub 2021 Dec 8. PubMed 34878953 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No — Availability of this study's data will later be determined according to Bayer's commitment to the EFPIA/PhRMA "Principles for responsible clinical trial data sharing". This pertains to scope, timepoint and process of data access. As such, Bayer commits to sharing upon request from qualified researchers patient-level clinical trial data, study-level clinical trial data, and protocols from clinical trials in patients for medicines and indications approved in the US and EU as necessary for conducting legitimate research. This applies to data on new medicines and indications that have been approved by the EU and US regulatory agencies on or after January 01, 2014. Interested researchers can use www.clinicalstudydatarequest.com to request access to anonymized patient-level data and supporting documents from clinical studies to conduct research. Information on the Bayer criteria for listing studies and other relevant information is provided in the Study sponsors section of the portal.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Mar 2020 to primary completion in Oct 2020, 6 months.

Results were first posted in Oct 2021, 1 year after primary completion.

Of 295 phase 4 interventional studies under Pain, half reached primary completion within 18 months of starting (the median), counting those still running; a quarter within 8 and three quarters within 33. This study's 6 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 5, 2020
First posted
Mar 13, 2020
StartActual
Mar 12, 2020
Primary completionActual
Oct 2, 2020
CompletionActual
Oct 5, 2020
Results first posted
Oct 7, 2021
Last update
Jul 14, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 14, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04307940
Lead sponsor
Bayer
Responsible party
Sponsor
First posted
Mar 13, 2020
Start date
Mar 12, 2020
Primary completion
Oct 2, 2020
Completion
Oct 5, 2020
Results posted
Oct 7, 2021
Last update
Jul 14, 2022

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Naproxen

Start the discussion